Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study

Journal of the American Medical Association

Volumn 286, Issue 1, 2001, Pages 64-70

  Albert, M A ^a   Danielson, E ^a   Rifai, N ^a   Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN;

ADULT; AGED; ANAMNESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; UNITED STATES;

EID: 0035806626     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.1.64     Document Type: Article

References (30)

1. Atherosclerosis: An inflammatory disease
2. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
3. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and lesional composition in the plaques of WHHL rabbits
4. HMG-CoA reductase inhibition with atorvastatin reduces neointimal inflammation in a rabbit model of atherosderosis
5. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
6. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Wantanabe heritable hyperlipidemic rabbits
7. Cerivastatin, an HMG-CoA reductase inhibitor, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
8. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
9. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
10. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
11. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
12. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the west of Scotland coronary prevention study
13. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
14. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
15. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
16. Low-grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
17. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
18. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. Inflammaton, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
20. Long-term effects of pravastatin on plasma concentration of C-reactive protein
21. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
22. The Pravastatin Inflammation/CRP Evaluation (PRINCE): Rationale and design
23. Evaluation of nine automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological application, II
24. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina
25. Hormone replacement therapy and increased plasma concentration of C-reactive protein
26. Effects of postmenopausal hormones on inflammation sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
27. Radomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
28. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein-a, and standard cholesterol screening as predictors of peripheral arterial disease
29. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels